☆ 4.8 Article

Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT

FRONTIERS IN IMMUNOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).

Richard S. Finn et al.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Peptide-based PET imaging agent of tumor TIGIT expression

Dinghu Weng et al.

Summary: In this study, a peptide-based PET imaging agent, Ga-68-DOTA-(TBP)-T-D-3, was developed to non-invasively detect tumor TIGIT expression in BALB/c mice. The results showed that Ga-68-DOTA-(TBP)-T-D-3 could specifically target 4T1 tumors and achieve the highest uptake at 0.5 h. This suggests the potential of Ga-68-DOTA-(TBP)-T-D-3 for detecting tumor TIGIT expression and assessing the therapeutic effect of immune checkpoint blockade.

EJNMMI RESEARCH (2023)

添加到收藏夹

Review Oncology

Anti-TIGIT therapies for solid tumors: a systematic review

A. Rousseau et al.

Summary: PD-(L)1, CTLA-4, and LAG-3 inhibitors have achieved breakthroughs in cancer treatment, but not all patients benefit from them. Therefore, new therapies such as anti-TIGIT antibodies are being investigated. In vitro studies have shown that TIGIT inhibition can restore antitumor response, and its combination with anti-PD-(L)1 therapies may improve survival synergistically. Clinical trials on TIGIT have demonstrated promising results, including objective response rates and progression-free survival. Targeting TIGIT appears to be a safe therapeutic approach with acceptable toxicity profiles, especially when combined with anti-PD-(L)1 antibodies. However, further research and phase III trials are needed to fully evaluate its efficacy.

ESMO OPEN (2023)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)

Odrade Gondry et al.

Summary: Macrophages play a vital role in the body, and anti-inflammatory macrophages targeting CD206 are involved in various diseases. This study evaluated the safety and biodistribution of a PET tracer targeting CD206 in human subjects, and found that the tracer was safe, rapidly cleared from the blood, and enabled high contrast imaging at 90 minutes after injection. Preliminary results showed higher tumor uptake in patients with disease progression.

JOURNAL OF NUCLEAR MEDICINE (2023)

添加到收藏夹

Article Oncology

TIGIT is a key inhibitory checkpoint receptor in lymphoma

James Godfrey et al.

Summary: This study reveals that TIGIT is widely expressed in lymphoma-infiltrating T cells (LITs) and frequently coexpressed with PD-1. In DLBCL, TIGIT(+) LITs often have significant contact with malignant B cells and exhibit dysfunctional cytokine production upon restimulation. In mouse experiments, combined blockade of PD-1 and TIGIT leads to complete rejection of lymphomas and significantly prolongs survival compared to monoblockade therapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹

Article Oncology

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer

J. Niu et al.

Summary: The study investigated the safety and efficacy of the anti-TIGIT antibody vibostolimab as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors. The combination therapy showed promising antitumor activity in patients with NSCLC and those refractory to anti-PD-1/PD-L1 treatment.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Preclinical and exploratory human studies of novel 68Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers

Xiaobo Wang et al.

Summary: The Ga-68-labeled D-peptide antagonist Ga-68-GP12 shows promise for PET imaging of TIGIT expression in cancers, with high affinity, specificity, and tumor uptake, indicating its potential as a companion diagnostic for anti-TIGIT therapies.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

添加到收藏夹

Article Oncology

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

Byoung Chul Cho et al.

Summary: The combination of tiragolumab and atezolizumab showed promising efficacy and safety as first-line treatment for NSCLC, with improved objective response rate and progression-free survival compared to placebo plus atezolizumab.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Immunology

TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer

Yaping Chen et al.

Summary: Combination immunotherapy based on immune checkpoint inhibitors (ICIs) has shown great success in cancer treatment, and the combination of ablation and immunotherapy has potential for the treatment of liver metastasis of colorectal cancer (CRC). The expression of TIGIT was up-regulated after microwave ablation (MWA), and the combination of MWA and TIGIT blockade significantly promoted the expansion and functions of CD8(+) tumor-infiltrating lymphocytes (TILs) and reshaped myeloid cells in the tumor microenvironment (TME).

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Review Oncology

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy

Eugene Y. Chiang et al.

Summary: Recent advances in understanding immune checkpoints have led to successful therapeutic strategies that have fundamentally changed oncology practice. Currently, only two immune therapies targeting CTLA-4 and PD-L1/PD-1 have been approved. TIGIT, a member of the PVR/nectin family, acts as a checkpoint inhibitor and regulates the activity of the costimulatory receptor CD226. Several TIGIT-directed blocking antibodies are currently being developed for clinical use.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Impaired TIGIT expression on B cells drives circulating follicular helper T cell expansion in multiple sclerosis

Hiromitsu Asashima et al.

Summary: The study revealed that B cell function in patients with multiple sclerosis is altered under CD40L and IL-21 stimulation, leading to T cell activation and driving disease pathogenesis.

JOURNAL OF CLINICAL INVESTIGATION (2022)

添加到收藏夹

Article Oncology

PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes

Travis Shaffer et al.

Summary: This study developed novel PET probes for TIGIT, demonstrating high specificity and immunoreactivity for TIGIT. In mouse models, these probes showed potential applications in diagnosis and monitoring of therapeutic responses in tumors.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade

Quentin Lecocq et al.

Summary: Recent advances in immune-oncology have led to the discovery of next-generation immune checkpoints, with LAG-3 being a prime target for cancer treatment. Utilizing single-domain antibodies for molecular imaging allows for noninvasive monitoring of LAG-3 expression on tumor-infiltrating lymphocytes, which could be crucial for predicting therapy outcomes.

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Review Oncology

A comprehensive comparison between camelid nanobodies and single chain variable fragments

Yasaman Asaadi et al.

Summary: By comparing the structure and properties of camelid antibodies (VHHs) and single-chain variable fragments (scFvs), it can be determined which one is more suitable for their respective therapeutic, diagnostic, and research applications.

BIOMARKER RESEARCH (2021)

添加到收藏夹

Review Immunology

TIGIT as an emerging immune checkpoint

H. Harjunpaa et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)

添加到收藏夹

Article Immunology

TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer

Danhua Xu et al.

IMMUNOBIOLOGY (2020)

添加到收藏夹

Article Chemistry, Multidisciplinary

Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours

Pieterjan Debie et al.

JOURNAL OF CONTROLLED RELEASE (2020)

添加到收藏夹

Review Oncology

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

Raju K. Vaddepally et al.

CANCERS (2020)

添加到收藏夹

Article Oncology

TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in Follicular Lymphoma

Zhi-Zhang Yang et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity

Adi Reches et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Cell Biology

Checkpoint Receptor TIGIT Expressed on Tim-1+ B Cells Regulates Tissue Inflammation

Sheng Xiao et al.

CELL REPORTS (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation

Jessica Bridoux et al.

BIOMOLECULES (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages

Catarina Xavier et al.

MOLECULAR IMAGING AND BIOLOGY (2019)

添加到收藏夹

Article Oncology

Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma

Gustav Stalhammar et al.

CANCER MEDICINE (2019)

添加到收藏夹

Article Oncology

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination

Mathieu Grapin et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Oncology

Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent

Katrijn Broos et al.

CANCERS (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use

Quentin Lecocq et al.

BIOMOLECULES (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Shuang Qin et al.

MOLECULAR CANCER (2019)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Jerome Galon et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

添加到收藏夹

Review Oncology

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Jonathan J. Havel et al.

NATURE REVIEWS CANCER (2019)

添加到收藏夹

Review Medicine, Research & Experimental

Theranostics in immuno-oncology using nanobody derivatives

Quentin Lecocq et al.

THERANOSTICS (2019)

添加到收藏夹

Review Oncology

Mechanisms of resistance to immune checkpoint inhibitors

Russell W. Jenkins et al.

BRITISH JOURNAL OF CANCER (2018)

添加到收藏夹

Article Oncology

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM

Alice L. Hung et al.

ONCOIMMUNOLOGY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

A. N. Niemeijer et al.

NATURE COMMUNICATIONS (2018)

添加到收藏夹

Article Oncology

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer

Ruea-Yea Huang et al.

ONCOIMMUNOLOGY (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Recognition of nectin-2 by the natural killer cell receptor T cell immunoglobulin and ITIM domain (TIGIT)

Felix A. Deuss et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2017)

添加到收藏夹

Article Oncology

Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers

Katrijn Broos et al.

ONCOTARGET (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Padmanee Sharma et al.

CELL (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Phase I Study of Ga-68-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma

Marleen Keyaerts et al.

JOURNAL OF NUCLEAR MEDICINE (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Shohei Koyama et al.

NATURE COMMUNICATIONS (2016)

添加到收藏夹

Review Oncology

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Suzanne L. Topalian et al.

NATURE REVIEWS CANCER (2016)

添加到收藏夹

Review Immunology

Antibody Aggregation: Insights from Sequence and Structure

Wei Li et al.

ANTIBODIES (2016)

添加到收藏夹

Article Medicine, Research & Experimental

TIGIT predominantly regulates the immune response via regulatory T cells

Sema Kurtulus et al.

JOURNAL OF CLINICAL INVESTIGATION (2015)

添加到收藏夹

Article Oncology

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function

Robert J. Johnston et al.

CANCER CELL (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-γ Production of Natural Killer Cells via β-Arrestin 2-mediated Negative Signaling

Man Li et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2014)

添加到收藏夹

Letter Oncology

Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies

M. Lemaire et al.

LEUKEMIA (2014)

添加到收藏夹

Article Immunology

Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR

Noa Stanietsky et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2013)

添加到收藏夹

Article Cell Biology

The tumor microenvironment at a glance

Frances R. Balkwill et al.

JOURNAL OF CELL SCIENCE (2012)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

In Vitro Analysis and In Vivo Tumor Targeting of a Humanized, Grafted Nanobody in Mice Using Pinhole SPECT/Micro-CT

Ilse Vaneycken et al.

JOURNAL OF NUCLEAR MEDICINE (2010)

添加到收藏夹

Article Immunology

A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC

Kent S. Boles et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2009)

添加到收藏夹

Article Immunology

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

Xin Yu et al.

NATURE IMMUNOLOGY (2009)

添加到收藏夹

Review Immunology

The immunobiology of cancer immunosurveillance and immunoediting

GP Dunn et al.

IMMUNITY (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.